ScholarLens Back to search
2014•Journal for ImmunoTherapy of CancerOpen access

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients

Troels Holz Borch, Rikke Andersen, Per Kongsted, Özcan Met, Mads Hald Andersen, Per thor Straten, Marco Donia, Inge Marie Svane

Open full text 1 citations

Abstract

Meeting abstracts Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has proven to be a powerful treatment option for patients with metastatic melanoma, even when heavily pretreated, with response rates of approximately 50% and durable complete responses in about 15%. However,

Open-access reader

About this research paper

What this paper is about

Meeting abstracts Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has proven to be a powerful treatment option for patients with metastatic melanoma, even when heavily pretreated, with response rates of approximately 50% and durable complete responses in about 15%. However,

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Meeting abstracts Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has proven to be a powerful treatment option for patients with metastatic melanoma, even when heavily pretreated, with response rates of approximately 50% and durable complete responses in about 15%. However,

Key concepts: Vemurafenib, Metastatic melanoma, Medicine, Melanoma, Oncology, Cancer research, Internal medicine

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients — Research Paper | ScholarLens